Anti-inflammatory and immunomodulatory efficacy of indig enous probiotic Lactobacillus plantarum Lp91 in colitis mouse model

Molecular Biology Reports

Volumn 39, Issue 4, 2012, Pages 4765-4775

  Duary, Raj Kumar ^a   Bhausaheb, Mache Amit ^b   Batish, Virender Kumar ^b   Grover, Sunita ^b  

^a TEZPUR UNIVERSITY   (India)

^b NATIONAL DAIRY RESEARCH INSTITUTE   (India)

Author keywords

Colitis; Cytokines; Lac tobacillus; Probiotic; RT qPCR

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; INTERLEUKIN 10; INTERLEUKIN 12P35; INTERLEUKIN 4; INTERLEUKIN 6; MUCIN 2; PROBIOTIC AGENT; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; AUTACOID; CYTOKINE; IMMUNOLOGIC FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL SURVIVAL; BACTERIUM CULTURE; COLITIS; CONTROLLED STUDY; COX1 GENE; COX2 GENE; DOWN REGULATION; DRUG EFFICACY; FECES ANALYSIS; GENE; GENE EXPRESSION REGULATION; IL 10 GENE; IL 12A GENE; IL 4 GENE; IL 6 GENE; IMMUNOMODULATION; IN VIVO STUDY; LACTOBACILLUS PLANTARUM; MOUSE; MUC2 GENE; NATIVE SPECIES; NONHUMAN; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECIES COMPARISON; STRAIN DIFFERENCE; TNF ALPHA GENE; UPREGULATION; ANIMAL; COLON; DISEASE MODEL; DRUG EFFECT; GENETICS; METABOLISM; MICROBIAL VIABILITY; MICROBIOLOGY; PATHOLOGY; STANDARD; TREATMENT OUTCOME;

LACTOBACILLUS PLANTARUM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; COLITIS; COLON; CYTOKINES; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; IMMUNOLOGIC FACTORS; INFLAMMATION MEDIATORS; LACTOBACILLUS PLANTARUM; MICE; MICROBIAL VIABILITY; MUCIN-2; PROBIOTICS; REAL-TIME POLYMERASE CHAIN REACTION; REFERENCE STANDARDS; TREATMENT OUTCOME;

EID: 84861447826     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-011-1269-1     Document Type: Article

References (45)

1. Sheil B, Shanahan F, O'Mahony L (2007) Probiotic effects on inflammatory bowel disease. J Nutr 137:819S-824S
2. Fedorak RN, Madsen KL (2004) Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis 10:286-299
3. Schreiber S, Heinig T, Thiele HG et al (1995) Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 108:1434-1444
4. Havenaar R, Ten Brink B, Huis Veld JHJ (1992) Selection of strains for probiotic use. In: Fuller R (ed) Probiotics: The scientific basis. Chapman and Hall, London, pp 209-224
5. McFarland L, Surawicz C, Greenberg R (1994) A randomised placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. J Am Med Assoc 271:1913-1918
6. Kruis W, Schutz E, Fric P et al (1997) Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 11:853-858
7. Foligne B, Zoumpopoulou G, Dewulf J et al (2007) A key role of dendritic cells in probiotic functionality. PLoS ONE 2:e313
8. Madsen KL, Doyle JS, Jewell LD et al (1999) Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 116:1107-1114
9. Sartor RB (2004) Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 126:1620-1633
10. Lammers KM, Vergopoulos A, Babel N et al (2005) Probiotic therapy in the prevention of pouchitis onset: decreased interleukin- 1beta, interleukin-8, and interferon-gamma gene expression. Inflamm Bowel Dis 11:447-454
11. Bibiloni R, Fedorak RN, Tannock GW et al (2005) VSL3 probiotic- mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 100:1539-1546
12. Schultz M, Veltkamp C, Dieleman LA et al (2002) Lactobacillus plantarum 299 V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. Inflamm Bowel Dis 8: 71-80
13. Gionchetti P, Rizzello F, Venturi A et al (2000) Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo controlled trial. Gastroenterology 119:305-309
14. Gionchetti P, Rizzello F, Helwig U et al (2003) Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebocontrolled trial. Gastroenterology 124:1202-1209
15. Gupta P, Andrew H, Kirschner BS et al (2000) Is Lactobacillus GG helpful in children with Crohn's diseasě Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr 31:453-457
16. FAO/WHO (2002) Working group report on drafting guidelines for the evaluation of probiotics in food London. Ontario, Canada
17. Christensen HR, Frokiaer H, Pestka JJ (2002) Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. J Immunol 168:171-178
18. Dombrowicz D, Nutten S, Desreumaux P et al (2001) Role of the high affinity immunoglobulin E receptor in bacterial translocation and intestinal inflammation. J Exp Med 193:25-34
19. Bustin SA, Benes V, Garson JA et al (2009) The MIQE guidelines: minimum information for publication of quantitative realtime PCR experiments. Clin Chem 55:611-622
20. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45
21. Rasmussen R (2001) Quantification on the LightCycler. In: Meuer S, Wittwer C, Nakagawara K (eds) Rapid cycle real-time PCR. Methods and applications. Springer Press, Heidelberg, pp 21-34
22. Pfaffl MW, Horgan GW, Dempfle L (2002) Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30:e36
23. Crittenden R, Karppinen S, Ojanen S et al (2002) In vitro fermentation of cereal dietary fibre carbohydrates by probiotic and intestinal bacteria. J Sci Food Agric 82:781-789
24. Harris RE (2007) Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer. Subcell Biochem 42:93-126
25. Wang Q, Takei Y, Kobayashi O et al (2009) Cyclooxygenase 2 modulates killing of cytotoxic T lymphocytes by colon cancer cells. J Clin Biochem Nutr 45:163-170
26. Brundnak MA (2001) Nutritional regulation of gene expression. Theory Biosci 120:64-75
27. Miller KS, Brudnak M (1994) Expression cloning: PCR versus episomal vectors for rescue of transfected genes. In: Sarkar G (ed) PCR in neuroscience (Methods in neuroscience, vol 26). Academic Press, Orlando, FL
28. Borruel N, Carol M, Casellas F et al (2002) Increased mucosal tumour necrosis factor a production in Crohn's disease can be regulated ex vivo by probiotic bacteria. Gut 51:659-664
29. Haller D, Bode C, Hammes WP et al (2000) Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures. Gut 47:79-87
30. Maassen CB, van Holten-Neelen C, Balk F et al (2000) Straindependent induction of cytokine profiles in the gut by orally administered Lactobacillus strains. Vaccine 18:2613-2623
31. Morita H, He F, Fuse T et al (2002) Adhesion of lactic acid bacteria to caco-2 cells and their effect on cytokine secretion. Microbiol Immunol 46:293-297
32. Ewaschuk JB, Dieleman LA (2006) Probiotics and prebiotics in chronic inflammatory bowel diseases. World J Gastroenterol 12:5941-5950
33. Lee JH, Lee B, Lee HS et al (2009) Lactobacillus suntoryeus inhibits pro-inflammatory cytokine expression and TLR-4-linked NF-kappaB activation in experimental colitis. Int J Colorectal Dis 24:231-237
34. Pavan S, Desreumaux P, Mercenier A (2003) Use of mouse models to evaluate the persistence, safety and immune modulation capacities of lactic acid bacteria. Clin Diagn Lab Immunol 10:696-701
35. Perdigon G, Maldonado Galdeano G, Valdez JC et al (2002) Interaction of lactic acid bacteria with the gut immune system. Eur J Clin Nutr 56:S21-S26
36. Hart AL, Lammers K, Brigidi P et al (2004) Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut 53:1602-1609
37. Chen L, Wang X, Cui Y et al (2009) Therapeutic effects of four strains of probiotics on experimental colitis in mice. World J Gastroenterol 15:321-327
38. Menard O, Butel M, Gaboriau-Routhiau V et al (2008) Gnotobiotic mouse immune response induced by Bifidobacterium sp. strains isolated from infants. Appl Environ Microbiol 74:660-666
39. Matsuzaki T, Takagi A, Ikemura H et al (2007) Intestinal microflora: probiotics and autoimmunity. J Nutr 137:798S-802S
40. Mastrangeli G, Corinti S, Butteroni C et al (2009) Effects of live and inactivated VSL#3 probiotic preparations in the modulation of in vitro and in vivo allergen-induced Th2 responses. Int Arch Allergy Immunol 150:133-143
41. Ulisse S, Gionchetti P, D'Alo S et al (2001) Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am J Gastroenterol 96:2691-2699
42. Hacini-Rachinel F, Gheit H, Luduec J et al (2009) Oral probiotic control skin inflammation by acting on both effector and regulatory T cells. PLoS ONE 4:e4903
43. Caballero F, Keller K, De Simone C et al (2007) The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol 292:G315-G322
44. Gaudier E, Michel C, Segain JP et al (2005) The VSL#3 probiotic mixture modifies microflora but does not heal chronic dextran sodium sulphate induced colitis or reinforce the mucus barrier in mice. J Nutr 135:2753-2761
45. Mattar AF, Teitelbaum DH, Drongowski RA et al (2002) Probiotics up-regulate MUC-2 mucin gene expression in a Caco-2 cell-culture model. Pediatr Surg Int 18:586-590